Search

Your search keyword '"Veenith, Tonny"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Veenith, Tonny" Remove constraint Author: "Veenith, Tonny"
268 results on '"Veenith, Tonny"'

Search Results

4. Accelerated immune ageing is associated with COVID-19 disease severity

5. Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis

7. Energy failure following traumatic brain injury : potential mechanisms and impact of normobaric hyperoxia

11. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

13. Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial

18. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

19. Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial.

26. The Effect of an Accelerated Renal Replacement Therapy Initiation Is Not Modified by Baseline Risk

27. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

28. SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation

29. SARS‐CoV‐2‐specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi‐System Syndrome

32. A Bayesian reanalysis of the standard versus accelerated initiation of renal-replacement therapy in acute kidney injury (STARRT-AKI) trial

34. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

35. In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens

36. CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

37. “Sugar or Salt” (SOS) trial protocol summary

40. Stability of OCT and OCTA in the Intensive Therapy Unit Setting

42. Individual Factors Including Age, BMI, and Heritable Factors Underlie Temperature Variation in Sickness and in Health: An Observational, Multi-cohort Study.

44. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection

45. Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial

46. Development of a high‐sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva

47. Establishing the prevalence of common, clinically relevant tissue-specific autoantibodies following SARS CoV-2 infection

48. Amyloid Imaging With Carbon 11–Labeled Pittsburgh Compound B for Traumatic Brain Injury

50. CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Catalog

Books, media, physical & digital resources